Accumulating evidence for the effect of chemotherapy on cognition

Journal of Clinical Oncology

Volumn 30, Issue 29, 2012, Pages 3568-3569

  Rodin, Gary ^a   Ahles, Tim A ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; APOLIPOPROTEIN E; CATECHOL METHYLTRANSFERASE;

ALZHEIMER DISEASE; ATTENTION; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVOR; COGNITION; COGNITIVE DEFECT; DEPTH PERCEPTION; DISEASE ASSOCIATION; DISEASE SEVERITY; DISTRESS SYNDROME; EDITORIAL; HUMAN; META ANALYSIS (TOPIC); MOTOR PERFORMANCE; NEUROPSYCHOLOGICAL TEST; NEUROTOXICITY; PRIORITY JOURNAL; QUALITY OF LIFE; RISK FACTOR; VISUAL MEMORY;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; COGNITION; COGNITION DISORDERS; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; MALE; MIDDLE AGED; PREVALENCE; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT;

EID: 84867591096     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.43.5776     Document Type: Editorial

References (13)

1. Silberfarb PM: Chemotherapy and cognitive defects in cancer patients. Annu Rev Med 34:35-46, 1983
2. Tannock IF, Ahles TA, Ganz PA, et al: Cognitive impairment associated with chemotherapy for cancer: Report of a workshop. J Clin Oncol 22:2233-2239, 2004 (Pubitemid 41095159)
3. Quesnel C, Savard J, Ivers H: Cognitive impairments associated with breast cancer treatments: Results from a longitudinal study. Breast Cancer Res Treat 116:113-123, 2009
4. Ahles TA, Saykin AJ, McDonald BC, et al: Longitudinal assessment of cognitive changes associated with adjuvant treatment for breast cancer: Impact of age and cognitive reserve. J Clin Oncol 28:4434-4440, 2010
5. Jansen CE, Cooper BA, Dodd MJ, et al: A prospective longitudinal study of chemotherapy-induced cognitive changes in breast cancer patients. Support Care Cancer 19:1647-1656, 2011
6. Phillips KM, Jim HS, Small BJ, et al: Cognitive functioning after cancer treatment: A 3-year longitudinal comparison of breast cancer survivors treated with chemotherapy or radiation and noncancer controls. Cancer 118:1925-1932, 2012
7. Tchen N, Juffs HG, Downie FP, et al: Cognitive function, fatigue, and menopausal symptoms in women receiving adjuvant chemotherapy for breast cancer. J Clin Oncol 21:4175-4183, 2003 (Pubitemid 46606186)
8. Jenkins V, Shilling V, Deutsch G, et al: A 3-year prospective study of the effects of adjuvant treatments on cognition in women with early stage breast cancer. Br J Cancer 94:828-834, 2006
9. Jim HSL, Phillips KM, Chait S, et al: Meta-analysis of cognitive functioning in breast cancer survivors previously treated with standard-dose chemotherapy. J Clin Oncol 30:3578-3587, 2012
10. Wefel JS, Vardy J, Ahles T, et al: International Cognition and Cancer Task Force recommendations to harmonise studies of cognitive function in patients with cancer. Lancet Oncol 12:703-708, 2011
11. Ahles TA, Saykin AJ, Noll WW, et al: The relationship of APOE genotype to neuropsychological performance in long-term cancer survivors treated with standard dose chemotherapy. Psychooncology 12:612-619, 2003 (Pubitemid 37086736)
12. Small BJ, Rawson KS, Walsh E, et al: Catechol-O-methyltransferase genotype modulates cancer treatment-related cognitive deficits in breast cancer survivors. Cancer 117:1369-1376, 2011
13. Wefel JS, Saleeba AK, Buzdar AU, et al: Acute and late onset cognitive dysfunction associated with chemotherapy in women with breast cancer. Cancer 116:3348-3356, 2010